全球 CD22 标靶疗法市场 - 已批准药物销售、技术平台和临床试验展望 (2026)

全球 CD22 标靶疗法市场 - 已批准药物销售、技术平台和临床试验展望 (2026) 报告的主要发现和要点：

• 当前与未来全球市场展望
• CD22 标靶疗法的洞察
• 已核准药物剂量、价格和销售分析
• 依地区和适应症划分的 CD22 标靶疗法发展趋势
• 正在进行临床试验的 CD22 标靶疗法：超过 20 种疗法
• 依公司、国家、适应症和研发阶段划分的 CD22 标靶疗法临床试验分析
• 各公司专有的 CD22 标靶疗法技术

对 CD22 标靶疗法的需求及其重要性报告

癌症治疗格局的不断变化推动了对标靶CD22蛋白疗法的需求。 CD22蛋白存在于B细胞表面，并在多种血液肿瘤中过度表达，包括急性淋巴性白血病、大B细胞淋巴瘤和毛细胞白血病。这些疗法可望提供更精准有效的治疗选择，尤其适用于已用尽常规治疗方案的復发或难治性疾病患者。本报告旨在为利害关係人提供CD22标靶疗法的现状概述，并深入了解推动该领域创新的临床试验、技术平台和关键参与者。

本报告包​​含的临床研究和试验见解

本报告对正在进行的CD22标靶临床研究和试验进行了全面分析，涵盖了广泛的地区、患者群体和治疗方法。本报告包​​含单药疗法和联合疗法的数据，重点介绍了将靶向 CD22 的药物与其他疗法（例如靶向 CD19 和 CD20 的疗法）联合使用的治疗潜力。本报告还概述了临床试验申办方，使利害关係人能够清楚了解推动 CD22 标靶疗法开发的公司、学术机构和研究组织。此外，报告还提供了区域性见解，使研究人员能够识别新兴市场以及 CD22 标靶疗法应用正在蓬勃发展或面临监管挑战的地区。

本报告涵盖的技术平台

本报告的一大亮点是其对创新技术平台的详细分析，这些平台正在显着改变 CD22 标靶疗法的开发方式。例如，Cellectis 公司的 TALEN®（转录活化因子样效应核酸酶）是一种基因编辑平台，可实现精确的基因组编辑，特别适用于 Lasme-cel (UCART22) 和 Eti-cel (UCART20x22) 等细胞疗法的开发。 TALEN® 技术能够实现高度精准的基因修饰，包括基因敲除、插入和缺失，从而开发出更有效、更具标靶性的疗法。本报告深入探讨了这些平台及其在 CD22 领域的应用，并阐述了这些技术如何重新定义细胞免疫疗法的未来。

参与 CD22 标靶疗法研发的关键公司

本报告也重点介绍了推动 CD22 标靶疗法研发的关键公司。这些公司包括辉瑞、阿斯特捷利康和 Umoja Biopharma 等大型生物技术和製药公司。新兴公司专注于细胞疗法和创新递送系统。本报告分析了这些公司正在采取的策略、已取得的进展以及它们将 CD22 标靶疗法推向癌症治疗前沿的潜力。深入了解每家公司的研发管线和开发重点，有助于利害关係人更准确地评估这一前景广阔的治疗领域的发展方向。

报告：CD22标靶疗法的未来发展方向

本报告旨在指导CD22标靶疗法的未来发展方向，该领域正不断发展演进。从CAR-T细胞疗法的进展到奈米抗体技术的整合，本报告指明了下一波创新浪潮。如前文所述，新型联合疗法和多标靶策略可望克服抗原逃脱和復发等关键挑战，从而提高治疗效果和患者预后。本报告将成为利害关係人了解CD22标靶疗法未来发展方向以及探索如何在快速发展的领域中取得成功的重要工具。

目录

第一章：研究方法

第二章：CD22简介

• CD22标靶疗法概述
• CD22在免疫学中的重要性

第三章：CD22生物学

• CD22的结构与功能
• 在B细胞发育与功能中的作用
• 在免疫反应中的作用机制

第四章：CD22标靶治疗方法

• 细胞疗法
• 抗体疗法
• 放射免疫偶联物
• 核疗法酸类

第五章：全球 CD22 标靶治疗市场展望

• 当前市场概况
• 未来市场机遇

第六章：赞助剂量、定价与销售洞察

• 概述与可用性洞察
• 定价与剂量洞察
• 销售洞察

第七章：CD22 标靶治疗区域市场分析

• 美国
• 欧洲

第八章：CD22 标靶治疗的发展与临床趋势（依适应症划分）

• 癌症
• 神经退化性疾病
• 自体免疫疾病与发炎性疾病疾病
• 传染病

第九章：全球 CD22 标靶治疗临床试验概论

• 依国家划分
• 依适应症划分
• 依机构划分
• 依阶段划分

第十章：全球 CD22 标靶治疗临床试验洞察（依公司、国家、适应症和阶段划分）

• 研究
• 临床前研究
• I 期研究
• I/II 期研究
• 註册前研究

第十一章：已上市 CD22 标靶治疗的临床洞察：依公司、国家、适应症和阶段划分

第十二章：全球 CD22 标靶治疗市场动态

• 推动因素和机遇
• 挑战与解决方案

第十三章：各公司CD22标靶治疗开发平台

第十四章：竞争格局

• ADC Therapeutics
• 阿斯特捷利康
• Autolus Therapeutics
• Cellectis
• Century Therapeutics
• Enterome
• Essen BioTech
• Kecellitics Biotech
• ME Therapeutics
• Miltenyi Biomedicine
• 南京艾奥生物技术
• NanoCell Therapeutics
• Onechain Immunotherapeutics
• 辉瑞
• Regeneron
• 上海亚科生物技术
• 希诺美生物科学
• TuHURA 生物科学公司
• Umoja 生物製药

Global CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms and Clinical Trials Insight 2026 Report Findings & Highlights:

• Current & Future Global Market Outlook
• Insight On CD22 Targeted Approaches
• Approved Drug Dosage, Price & Sales Insight
• CD22 Targeted Therapies Development Trends By Region & Indications
• CD22 Targeted Therapies In Clinical Trials: > 20 Therapies
• CD22 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
• CD22 Targeted Therapies Proprietary Technologies By Company

CD22 Targeted Therapies Need & Why This Report?

As the landscape of cancer therapies evolves, there is an increasing demand for treatments that specifically target the CD22 protein, which is found on the surface of B-cells and is overexpressed in several blood cancers, including acute lymphoblastic leukemia, large B-cell lymphoma and hairy cell leukemia. These therapies offer the potential for more precise, effective options, especially for patients with conditions in relapsed or refractory states who have exhausted conventional therapies. The report is designed to give stakeholders an overview of the current landscape regarding CD22 targeted therapies, offering an understanding of clinical trials, technological platforms, and key players driving innovation in the space.

Clinical Studies & Trials Insight Included In Report

This report provides comprehensive analysis for ongoing clinical studies and trials targeting CD22, covering a wide array of geographies, patient segments, and therapeutic approaches. Insights include data on monotherapies and combination therapies, highlighting the therapeutic potential of combining agents targeting CD22 with other treatments, such as CD19 or CD20 directed therapies. The report also covers trial sponsors, giving stakeholders a clear view on which companies, academia, and research institutes are advancing the development of treatments utilizing CD22. Additionally, it provides regional insights that allow for the identification of emerging markets and regions where the adoption of CD22 targeted therapies is gaining momentum or facing regulatory challenges.

Technology Platforms Included In Report

One of the key highlights of the report is the in-depth analysis of innovative technology platforms that are dramatically changing how CD22 targeted therapies are developed. For example, TALEN(R) (Transcription Activator-Like Effector Nucleases) by Cellectis is a gene-editing platform that enables precise genome editing and proves especially instrumental in cell therapy development, including Lasme-cel (UCART22) and Eti-cel (UCART20x22). TALEN(R) technology enables highly accurate gene modifications, such as knockouts, insertions, and deletions, allowing for the manufacturing of more effective and targeted treatments. The report provides an in-depth review of such platforms and their application in the CD22 space, giving insight into how these technologies are redefining the future of cell-based immunotherapies.

Leading Companies Engaged In R&D Of CD22 Targeted Therapies

The report also profiles the leading companies driving research and development in CD22 targeted therapies, including major biotech and pharmaceutical companies such as Pfizer, AstraZeneca, and Umoja Biopharma, among others. Emerging players specialize in cell-based therapies and innovative delivery systems. This report analyzes the strategies being pursued, progress made, and the potential for these companies to bring CD22 targeted therapies to the forefront of cancer treatment. Gaining insight into a company's research pipeline and development priorities enables stakeholders to more accurately assess the direction of this exciting therapeutic area.

Report Indicating Future Direction Of CD22 Targeted Therapies

This report provides the future direction of these therapies as the landscape of CD22 targeted therapies continuously evolves. The next waves of innovation, from advances in CAR-T cell therapies to the integration of nanobody based technologies, are identified in this report. As explained, new combinations and multi target approaches have the potential to overcome major challenges such as antigen escape and relapse and, therefore, will drive improved efficacy and patient outcomes. This report is an important tool for stakeholders seeking to understand where CD22 targeted therapies are headed and how to position themselves for success in this rapidly developing field.

Table of Contents

1. Research Methodology

2. Introduction To CD22

• 2.1 Overview Of CD22 Targeted Therapies
• 2.2 Importance Of CD22 In Immunology

3. Biology Of CD22

• 3.1 Structure & Function of CD22
• 3.2 Role In B-cell Development & Function
• 3.3 Mechanisms Of Action In Immune Response

4. CD22 Targeted Approaches

• 4.1 Cell Therapies
• 4.2 Antibody Therapies
• 4.3 Radioimmunoconjugates
• 4.4 Nucleic Acids

5. Global CD22 Targeted Therapies Market Outlook

• 5.1 Current Market Scenario
• 5.2 Future Market Opportunities

6. Besponsa - Dosage, Price & Sales Insight

• 6.1 Overview & Availability Insight
• 6.2 Pricing & Dosage Insight
• 6.3 Sales Insight

7. CD22 Targeted Therapies Regional Market Analysis

• 7.1 US
• 7.2 Europe

8. CD22 Targeted Therapies Development & Clinical Trends By Indication

• 8.1 Cancer
• 8.2 Neurodegenerative Diseases
• 8.3 Autoimmune & Inflammatory Diseases
• 8.4 Infectious Diseases

9. Global CD22 Targeted Therapy Clinical Trials Overview

• 9.1 By Country
• 9.2 By Indication
• 9.3 By Organization
• 9.4 By Phase

10. Global CD22 Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase

• 10.1 Research
• 10.2 Preclinical
• 10.3 Phase I
• 10.4 Phase I/II
• 10.5 Preregistration

11. Marketed CD22 Targeted Therapies Clinical Insight By Company, Country, Indication & Phase

12. Global CD22 Targeted Therapies Market Dynamics

• 12.1 Drivers & Opportunities
• 12.2 Challenges & Solutions

13. CD22 Targeted Therapies Development Platforms By Company

14. Competitive Landscape

• 14.1 ADC Therapeutics
• 14.2 AstraZeneca
• 14.3 Autolus Therapeutics
• 14.4 Cellectis
• 14.5 Century Therapeutics
• 14.6 Enterome
• 14.7 Essen BioTech
• 14.8 Kecellitics Biotech
• 14.9 ME Therapeutics
• 14.10 Miltenyi Biomedicine
• 14.11 Nanjing IASO Biotechnology
• 14.12 NanoCell Therapeutics
• 14.13 Onechain Immunotherapeutics
• 14.14 Pfizer
• 14.15 Regeneron
• 14.16 Shanghai Yake Biotechnology
• 14.17 SinoMab Bioscience
• 14.18 TuHURA Biosciences
• 14.19 Umoja Biopharma

List of Figures

• Figure 2-1: CD22 As A Therapeutic Target
• Figure 2-2: Evolution Of CD22 Targeted Therapy
• Figure 2-3: CD22 In Immune Regulation
• Figure 2-4: CD22 In The B-Cell Signaling Network
• Figure 2-5: How CD22 Dampens BCR Signaling
• Figure 3-1: Domain Architecture Of CD22
• Figure 3-2: CD22 Mediated Inhibition Of BCR Signaling
• Figure 3-3: Dual Signaling Roles Of CD22
• Figure 3-4: CD22 Oligomerization & B-Cell Activation Threshold
• Figure 3-5: CD22 Adhesion & Immune Synapse Positioning
• Figure 3-6: CD22 In Calcium Regulation
• Figure 3-7: CD22's Multi-Layered Control Of Immune Responses
• Figure 4-1: CD22 Targeted CAR-T Cell Therapy - Mechanism
• Figure 4-2: Targeting CD22 After CD19 Antigen Escape
• Figure 4-3: Multi-Antigen CAR Concept Featuring CD22
• Figure 4-4: CD22 Targeted Antibody Based Therapies
• Figure 4-5: Besponsa - Mechanism Of Action
• Figure 4-6: Lumoxiti - Mechanism Of Action
• Figure 4-7: CD22-Targeted Radioimmunoconjugates - Mechanism Of Action
• Figure 4-8: CD22 Radioimmunoconjugates - Advantages
• Figure 4-9: CD22 Nucleic Acid Targeting Approaches
• Figure 4-10: Targeting CD22 With RNA-Based Therapeutics
• Figure 5-1: CLIC-02 Phase 1 (NCT06208735) Study - Initiation & Completion Year
• Figure 5-2: Global CD22 Targeted Therapies Market - Future Opportunities
• Figure 6-1: Besponsa - Approval Year By Region
• Figure 6-2: Besponsa - Cost Of Supply By Region, November'2025
• Figure 6-3: Besponsa - Global Annual Sales (US$ Million), 2020-2023
• Figure 6-4: Besponsa - Global Sales by Region (US$ Million), 2023
• Figure 6-5: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2023
• Figure 8-1: SIDNEY Phase 1/2 (NCT04669171) Study - Initiation & Completion Year
• Figure 8-2: BZE2204-A-01 Phase 1 (NCT06446128) Study - Initiation & Completion Year
• Figure 8-3: BZE2204-C-01 Phase 1 (NCT07174843) Study - Initiation & Completion Year
• Figure 9-1: Global - Number Of CD22 Targeted Therapy Clinical Trials By Country, 2026
• Figure 9-2: Global - Number Of CD22 Targeted Therapy Clinical Trials By Indication, 2026
• Figure 9-3: Global - Number Of CD22 Targeted Therapy Clinical Trials By Organization, 2026
• Figure 9-4: Global - Number Of CD22 Targeted Therapy Clinical Trials By Phase, 2026
• Figure 12-1: Global CD22 Targeted Therapies Market - Drivers & Opportunities
• Figure 12-2: Global CD22 Targeted Therapies Market - Challenges & Solutions
• Figure 13-1: TRAAC - Tallac Therapeutics
• Figure 13-2: VivoVec Platform - Unique Features
• Figure 13-3: OncoMimics Platoform
• Figure 13-4: Cellectis - TALEN Technology

List of Tables

• Table 3-1: CD22 Functions Across B-Cell Stages
• Table 4-1: CD22 Directed Antibody Based Therapies